TTD | Drug: D0S2LQ

Drug General Information
Drug ID	D0S2LQ
Former ID	DCL000940
Drug Name	PYY3-36
Indication	Obesity [ICD9: 278; ICD10:E66]		Discontinued in Phase 2	[536372], [538947]
Company	Nastech; Merck
Target and Pathway
Target(s)	Neuropeptide Y receptor type 2	Target Info	Agonist	[536122]
KEGG Pathway	Neuroactive ligand-receptor interaction
Reactome	Peptide ligand-binding receptors
Reactome	G alpha (i) signalling events
WikiPathways	GPCRs, Class A Rhodopsin-like
	Peptide GPCRs
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 536372	Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs. 2007 Mar;12(1):75-95.
Ref 538947	(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1554).
Ref 536122	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.

Drug Information